Economic impact of disease progression in follicular non-Hodgkin lymphoma. - Wikidata - wikimedia - TriplyDB

Economic impact of disease progression in follicular non-Hodgkin lymphoma.

Economic impact of disease progression in follicular non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q35536558

about

Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.

P2860

Q37008507-73D64CDB-B878-4255-919C-3F8793EFF286

P2860

Economic impact of disease progression in follicular non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q35536558

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Economic impact of disease progression in follicular non-Hodgkin lymphoma.

@ast

Economic impact of disease progression in follicular non-Hodgkin lymphoma.

@en

type

label

Economic impact of disease progression in follicular non-Hodgkin lymphoma.

@ast

Economic impact of disease progression in follicular non-Hodgkin lymphoma.

@en

prefLabel

Economic impact of disease progression in follicular non-Hodgkin lymphoma.

@ast

Economic impact of disease progression in follicular non-Hodgkin lymphoma.

@en

P1433

Q35536558-5B5D331B-240D-4AC0-AD70-ED650FE1A5DA

P1476

Q35536558-F9AE7810-91F8-4D6F-909C-BF922D133957

P2093

Q35536558-01F4E908-2267-43BC-ABFA-CDC3BCBBBF14

Q35536558-1293F076-5900-450B-85C6-31B82DBB61BF

Q35536558-158893C1-9AFE-43FC-A96B-92A7802018D3

Q35536558-282747B3-D771-4677-926E-1031D4413DBA

Q35536558-40C527B6-654B-410D-9535-C5AA15B1015C

Q35536558-96857AC6-5DBA-4408-A66A-4B42088C5DF3

Q35536558-E8CC7A0A-59EE-4C40-AB25-B6A434A6CEA9

P2860

Q35536558-058AD415-F0A1-45BC-9E2D-AC724DA351FE

Q35536558-0AE8D118-68F8-44A5-9092-FB0B8B62B0E0

Q35536558-0C2D6615-D366-4801-A41D-DB9B6C07CFA8

Q35536558-0F05AD0A-334C-4320-B1F0-8B3F037D54F7

Q35536558-1E4A941D-1A0D-4863-AA5C-DFEF5DDBC1F3

Q35536558-2B6A28D9-48E7-4710-8643-EF4804930482

Q35536558-2DFA2D27-BB55-469E-A369-E03B8C8FB9A9

Q35536558-426E5BF4-F43C-472D-9515-A7E08A28CF4F

Q35536558-4C416610-784E-4D2B-B778-F0B5FFB32D70

Q35536558-587FA28B-2805-418D-9F00-D50B87639C5B

P304

Q35536558-9EA04789-B8EC-4394-B5E4-8710C1F6AA2D

P31

Q35536558-0425976A-6FEC-4414-88D6-029FC19EAB8E

P356

Q35536558-14946DCA-620C-4DC2-9C59-C750FEA822BE

P433

Q35536558-49DD4DAE-5116-450A-8AE4-8373BCDDF71B

P478

Q35536558-3B28DEC6-0FFA-40C2-BCDC-3D20427B4B2E

P577

Q35536558-C1309C80-8088-484A-A419-335522DC5723

P5875

Q35536558-44376B15-1DAB-4999-9EC1-C0BFDC4A7547

P698

Q35536558-5884DE72-1F5E-4FEC-9281-011065D4AB65

P932

Q35536558-459B49AF-E760-42FD-9D5F-613076A70EF4

P356

10428194.2011.592623

P1433

Leukemia & Lymphoma

P1476

Economic impact of disease progression in follicular non-Hodgkin lymphoma.

@en

P2093

Carolina Reyes

http://www.w3.org/2001/XMLSchema#string

Clara Chen

http://www.w3.org/2001/XMLSchema#string

Joseph Darragh

http://www.w3.org/2001/XMLSchema#string

Kavita Sail

http://www.w3.org/2001/XMLSchema#string

Michael Forsyth

http://www.w3.org/2001/XMLSchema#string

Roy Beveridge

http://www.w3.org/2001/XMLSchema#string

Sacha Satram-Hoang

http://www.w3.org/2001/XMLSchema#string

P2860

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

Using heteroskedasticity-consistent standard error estimators in OLS regression: An introduction and software implementation

Estimating health care costs related to cancer treatment from SEER-Medicare data.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

Cost of care for cancer in a health maintenance organization.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Follicular lymphoma: a therapeutic update.

Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.

P304

2117-2123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2011.592623

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51482671

http://www.w3.org/2001/XMLSchema#string

P698

21745172

http://www.w3.org/2001/XMLSchema#string

P932

3211193

http://www.w3.org/2001/XMLSchema#string